According to the Cognate CDMO agreement, it does not expire until 5 years after DCVax-L is commercially approved by the FDA or another regulatory authority.
As a result, the framework for the CDMO contract agreement with Cognate / CRL is still in place, but it will need to be updated to reflect updated DCVax-L production costs (based on commercial production scale instead of clinical trial production scale), and the number of clean rooms that will be dedicated to DCVax-L, and possibly how Flaskworks will be integrated into the production process, and what impact that will have on DCVax-L production costs.
Market Data 
Markets 
AI
